Open original FDA record ↗Recall record
- FDA identifier
- Z-0509-2016
- Company in FDA record
- Ameditech Inc
- FDA record creation date
- Dec 24, 2015
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class III
Reason stated in the source
Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Source facts
- Action
- A Medical Device Labeling Correction letter was sent on 11/16/15 to distributors and end users to inform them that Ameditechs Drugs of Abuse Tests have shown reduced reactivity for up to two (2) of the nineteen (19) BZO compounds for which specificity information is provided in the product insert. The letter informs the customers that the particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. Customers with questions are instructed to contact Ameditech at (844) 616-4453 or email at amt.fieldaction@alere.com.
- Initiated
- 2015-11-16
- Root cause
- Nonconforming Material/Component
- Terminated
- 2016-11-09
- Distribution
- Nationwide Distribution.
- Recall number
- Z-0509-2016
- Recall status
- Terminated
- CDRH record ID
- 141907
- FDA record created
- 2015-12-24
- Recall event number
- 72651